Login

CymaBay Therapeutics, Inc. SEC Filings

Filed On Filing
01 Apr 2024 15-12G
28 Mar 2024 EFFECT
28 Mar 2024 EFFECT
28 Mar 2024 EFFECT
28 Mar 2024 EFFECT
28 Mar 2024 EFFECT
22 Mar 2024 Form 4: Loewy Caroline M, Director

Disposed of 283,460 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: McWherter Charles, President of R&D

Returned 46,938 shares to the issuer · Disposed of 1,688,412 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Lefebvre Eric, Director

Disposed of 154,010 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Dorling Janet, Director

Disposed of 161,010 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Shantharam Harish, Chief Financial Officer

Returned 20,125 shares to the issuer · Disposed of 434,750 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Dickinson Klara, Chief Regulatory Officer

Returned 21,000 shares to the issuer · Disposed of 1,301,111 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Quinlan Paul T, General Counsel

Returned 70,262 shares to the issuer · Disposed of 682,968 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 S-8 POS
22 Mar 2024 S-8 POS
22 Mar 2024 S-8 POS
22 Mar 2024 Form 4: Wills Robert James, Director

Returned 30,000 shares to the issuer · Disposed of 332,460 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Shah Sujal, Director

Returned 406,670 shares to the issuer · Disposed of 4,025,981 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 Form 4: Wiggans Thomas G, Director

Disposed of 186,010 Employee Stock Option (right to buy) (Disposition to Issuer)

22 Mar 2024 S-8 POS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support